Omeros Corporation (NASDAQ:OMER) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “

Several other research firms have also commented on OMER. WBB Securities reiterated a “buy” rating and issued a $75.00 price target on shares of Omeros Corporation in a research report on Monday. FBR & Co reiterated an “outperform” rating and issued a $38.00 price target on shares of Omeros Corporation in a research report on Tuesday. Maxim Group lowered their price target on shares of Omeros Corporation from $30.00 to $19.00 and set a “buy” rating on the stock in a research report on Wednesday, August 10th. Wedbush reiterated an “outperform” rating and issued a $56.00 price target (down from $62.00) on shares of Omeros Corporation in a research report on Thursday, August 11th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 price target on shares of Omeros Corporation in a research report on Wednesday, August 10th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $32.45.

Analyst Recommendations for Omeros Corporation (NASDAQ:OMER)

Shares of Omeros Corporation (NASDAQ:OMER) opened at 7.50 on Wednesday. The stock’s market cap is $294.70 million. The firm has a 50-day moving average price of $10.41 and a 200-day moving average price of $11.57. Omeros Corporation has a 12 month low of $7.20 and a 12 month high of $16.80.

Omeros Corporation (NASDAQ:OMER) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.18. The company earned $10 million during the quarter, compared to analysts’ expectations of $9.80 million. During the same period last year, the business posted ($0.44) earnings per share. The company’s quarterly revenue was up 212.5% on a year-over-year basis. Equities analysts expect that Omeros Corporation will post ($1.55) EPS for the current fiscal year.

In related news, VP Marcia S. Kelbon sold 16,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $10.91, for a total transaction of $174,560.00. Following the sale, the vice president now owns 179,597 shares in the company, valued at $1,959,403.27. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Marcia S. Kelbon sold 15,900 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $11.56, for a total transaction of $183,804.00. Following the sale, the vice president now owns 179,497 shares in the company, valued at approximately $2,074,985.32. The disclosure for this sale can be found here. Corporate insiders own 13.60% of the company’s stock.

A number of hedge funds have recently made changes to their positions in OMER. Sheaff Brock Investment Advisors LLC purchased a new stake in shares of Omeros Corporation during the second quarter worth about $105,000. Bourgeon Capital Management LLC purchased a new stake in shares of Omeros Corporation during the second quarter worth about $158,000. BlackRock Advisors LLC raised its stake in shares of Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 173 shares during the period. Mesirow Financial Investment Management Equity Management purchased a new stake in shares of Omeros Corporation during the second quarter worth about $244,000. Finally, Gradient Investments LLC raised its stake in shares of Omeros Corporation by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock worth $282,000 after buying an additional 814 shares during the period. Hedge funds and other institutional investors own 48.04% of the company’s stock.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.